When to Sell a Home Health Agency: Reading the 2026 Timing Signals
On July 1, 2026, CMS issued the CY 2027 Home Health Prospective Payment System proposed rule (CMS-1844-P), and it hands agency owners a mixed message: a net 2.4% aggregate payment increase for 2027, paired with a proposed temporary 3.0% cut that keeps recouping past PDGM overpayments. If you own a Medicare-certified agency, that split is the backdrop to a question a lot of owners are sitting with right now: when is the right time to sell a home health agency, and does 2026 qualify. This guide walks through the timing signals, the current numbers, and how to read your own situation, so the decision is grounded in evidence rather than a gut feeling.
As of July 2026, buyer demand has firmed after a soft stretch, multiples have ticked up modestly over the prior twelve months, and private-equity sponsors who have held platforms for five to seven years are motivated to transact. None of that guarantees a good outcome for any single agency. What it does is widen the window for owners whose financials, market, and personal readiness happen to line up. Below, we break down each of those levers.
When is the right time to sell a home health agency?
The right time to sell a home health agency is when three levers align: your financials are clean and growing, the buyer market is active, and you are personally ready to step back. In 2026, the first two are unusually well aligned, which is why more owners are running the numbers now rather than waiting for a reimbursement environment that may never feel calm.
Think of timing as the overlap of three circles. The first is financial readiness: trailing EBITDA that a buyer can verify, a diversified payer mix, dependable census, and books that survive diligence without surprises. The second is market conditions: how many qualified buyers are active, how much capital they need to deploy, and where multiples sit for an agency like yours. The third is personal readiness: your energy for another survey cycle, your succession plan, your life stage, and what you would do next. When all three overlap, you are selling from strength. When only one or two do, you are usually better off preparing than listing.
Most owners come to us six to nine months later than they should. The cost of waiting is rarely dramatic in any single quarter. It shows up slowly, as owner dependency deepens, a key referral source shifts, or a reimbursement adjustment compresses the margin a buyer underwrites. Reading the signals early is what preserves optionality.
How does the CMS CY 2027 proposed rule change the timing math?
The CY 2027 proposed rule improves the headline number while keeping the underlying pressure in place, so it sharpens rather than settles the timing question. CMS proposed a net 2.4% aggregate increase for 2027, its first year in three without an additional permanent PDGM adjustment, but it also proposed continuing a temporary 3.0% reduction to the 30-day base rate to recoup prior overpayments.
Here is what sits inside that headline. The CY 2027 payment update is 2.1%, or roughly $420 million more in aggregate Medicare spending on home health, offset by a small fixed-dollar-loss adjustment, for a net gain of about 2.4% compared with 2026 (source: CMS Fact Sheet CMS-1844-P, July 2026). The relief is that CMS did not layer on another permanent behavioral cut this cycle. The catch is the temporary 3.0% recoupment, which continues clawing back overpayments tied to the shift to PDGM. CMS estimates cumulative temporary-adjustment amounts near $4.9 billion through CY 2025, with the CY 2027 slice projected around $500 million (source: Applied Policy, July 2026). The comment window runs through August 31, 2026, so the final numbers can still move.
For sale timing, the takeaway is not the single-year percentage. It is the pattern. Buyers underwrite the forward margin, and the CY 2027 proposal signals that Medicare rate-setting will keep oscillating between modest raises and ongoing recoupment. That choppiness is exactly why disciplined buyers pay a premium for agencies that can prove durable cash flow through it. The proposed rule also tightens provider enrollment, including a move to make Medicare revocations retroactive, which raises the bar on compliance hygiene for anyone entering a transaction. Clean enrollment and survey history are becoming a gating item, not a nice-to-have.
| Factor | CY 2026 Final Rule (Nov 2025) | CY 2027 Proposed Rule (Jul 2026) |
|---|---|---|
| Net aggregate payment change | About -1.3% (~$220M cut) | About +2.4% (~$420M increase) |
| Permanent PDGM adjustment | -1.023% permanent | None proposed (first time in 3 years) |
| Temporary recoupment | -3.0% temporary | -3.0% temporary (continues) |
| Provider enrollment | Existing safeguards | Tighter; retroactive revocations proposed |
| Status | Final, in effect for 2026 | Proposed; comments due Aug 31, 2026 |
Is 2026 a good time to sell a home health agency?
For a well-run agency, 2026 is one of the more favorable sale windows in recent years, because buyer activity has rebounded and multiples have firmed while many owners remain on the sidelines. The imbalance between motivated capital and prepared sellers tends to work in the prepared seller’s favor.
The deal data backs this up. According to the Mertz Taggart Q1 2026 Home-Based Care M&A report, 22 transactions closed in the first quarter, split across hospice (10), home care (9), and home health (6). Home health’s six deals were its strongest quarter in over a year, up from three in the prior quarter, and managing partner Cory Mertz noted that multiples have risen a little over the past twelve months. The headline transaction was Kinderhook Industries acquiring Enhabit for about $1.1 billion, a 10.2x EBITDA multiple on roughly $108 million of EBITDA (source: Mertz Taggart, 2026; Hospice News, 2026).
Larger platform moves tell the same story. General Atlantic acquired TEAM Services Group from Alpine Investors for about $3 billion including debt, one of the biggest home-based-care deals of the year. Roughly 41% of 2026 home health and hospice deals have been committed by private-equity buyers, and many of those sponsors have held their platforms for five to seven years, which creates pressure to return capital to their investors and fuels appetite for add-on acquisitions (source: Levin Associates, 2026; Mertz Taggart, 2026). For an owner, motivated buyers with deployment pressure are a favorable backdrop, provided your agency is ready to withstand their diligence.
| 2026 sell-side signal | Reading | What it means for you |
|---|---|---|
| Buyer demand and deal volume | Favorable | Home health closed its best quarter in over a year in Q1 2026 |
| Multiples trend | Firming | Values up modestly over the past 12 months for quality agencies |
| PE capital pressure | Favorable | Sponsors holding 5 to 7 years need to transact; add-on appetite is high |
| Reimbursement | Mixed | Net +2.4% for 2027, but temporary 3.0% recoupment continues |
| Compliance scrutiny | Rising | Tighter enrollment rules reward clean survey and billing history |
How are home health agencies valued in 2026, and how does timing move the number?
Home health agencies are valued primarily on a multiple of adjusted EBITDA, and timing moves the number by changing both the EBITDA a buyer will credit and the multiple they will pay. Sell when your trailing earnings are strong and the market is active, and you are negotiating from the top of both ranges rather than the bottom.
The mechanics are straightforward. A buyer starts with your trailing twelve-month EBITDA, then normalizes it: adding back genuine owner discretionary expenses, removing one-time items, and adjusting owner compensation to a market rate for a replacement administrator. The credibility of those add-backs matters enormously. In a tighter market, buyers scrutinize add-backs harder, so an owner who has already cleaned up the books captures more of the value. Multiples then vary with scale, payer mix, accreditation, star ratings, and the durability of referral relationships.
The ranges below are illustrative and conditioned. Actual multiples depend on payer mix, geographic footprint, staff retention, referral concentration, and compliance history, and no range is a quote. They are meant to show how profile drives value, and why timing your sale to a period of strong earnings and active buyers matters.
| Agency profile | Typical basis | Illustrative EBITDA range |
|---|---|---|
| Small private-duty / non-medical, owner-dependent | SDE or low EBITDA multiple | Roughly 3.0x to 5.0x |
| Established Medicare-certified home health | Adjusted EBITDA | Roughly 6.0x to 8.0x |
| Scaled regional platform, diversified payers, clean compliance | Adjusted EBITDA | Several turns higher; 9.0x or more |
| Reference point: Enhabit / Kinderhook (2026) | Public transaction | 10.2x EBITDA |
If you want a fast, no-obligation read on where your agency might land, the ValueMyBusiness valuation calculator gives you a starting range in a few minutes. Treat it as a directional estimate, then let a healthcare M&A advisor refine it against your actuals.
What is your agency worth in today’s market? Get a free, confidential valuation range and a candid read on your timing. We only work in healthcare, and our fee is success-based, so the first conversation costs you nothing but time.
Should I sell my home health agency now, or wait?
Sell now if your earnings are strong, buyers are active, and you are ready to move on; wait if your margins are recovering, you have concrete improvements underway that will lift value, and you can execute them without burning out. The decision is less about calling the market and more about matching the sale to your agency’s readiness.
The case for selling in 2026 rests on the buyer environment. Demand has rebounded, multiples are firming, and sponsors with capital to deploy are actively hunting add-ons. If your agency is prepared, you are meeting that demand at a good moment, and you avoid the risk that the next reimbursement cycle or a personal event forces a rushed sale later. Selling from strength almost always beats selling under pressure.
The case for waiting is specific, not general. Wait if you have a clear, fundable plan to grow census, diversify payers, or reduce owner dependency over the next twelve to eighteen months, and you have the energy to see it through. Those improvements can raise both the EBITDA and the multiple, and a stronger agency in an active market is worth more than a good agency sold too early. What rarely pays is waiting passively, hoping reimbursement gets easier. It has not, and the CY 2027 proposal suggests the oscillation continues. The owners who benefit from waiting are the ones who use the time to build value, not the ones who use it to postpone a decision.
What are the signs it is time to sell your home health agency?
The clearest signs it is time to sell are declining personal energy for the work, deepening owner dependency, a growth ceiling you cannot break alone, and unsolicited buyer interest arriving while your numbers are still strong. When several of these appear together, preparation should start immediately.
- You have become the bottleneck. If referrals, key relationships, or clinical oversight run through you personally, that owner dependency caps both your growth and your multiple. It is easier to fix before a sale than to explain during one.
- Reimbursement fatigue is setting in. Another PDGM recoupment cycle, another survey, another payer authorization fight. If you no longer have the appetite for the regulatory grind, that is a legitimate, common reason to plan an exit.
- You have hit a growth ceiling. When the next stage of growth needs capital, scale, or a management bench you cannot build alone, a strategic or PE buyer may unlock value you cannot capture solo.
- Buyers are calling. Unsolicited interest while your census and margins are strong is a signal that you are a desirable asset now. Fielding those calls with an advisor beats negotiating one-off from a position of surprise.
- Your life stage is shifting. Retirement, health, a partnership change, or simply wanting your time back are valid drivers. The goal is to sell on your timeline, from strength, not on someone else’s.
How do I prepare a home health agency for sale?
Preparing a home health agency for sale means getting your financials, compliance, and operations to a state where a buyer’s diligence confirms your story rather than picking it apart. The following steps, started six to twelve months ahead, protect both your value and your negotiating position.
- Clean up the financials. Produce accrual-based statements, reconcile them, and document every add-back you will ask a buyer to credit. Unverifiable add-backs are where value quietly leaks.
- Normalize owner compensation. Restate your pay and any discretionary expenses to a market-rate replacement administrator, so adjusted EBITDA reflects the true earning power a buyer inherits.
- Diversify and document payer mix. Show the split across Medicare, Medicare Advantage, Medicaid, and private pay, and demonstrate that no single payer or referral source can sink the agency.
- Shore up compliance. Assemble a clean survey history, accreditation records, and billing-audit results. With enrollment scrutiny rising in 2027, this is now a gating item.
- Reduce owner dependency. Delegate referral relationships and clinical oversight to a management team, so the agency demonstrably runs without you.
- Stabilize staffing. Track and improve caregiver and clinician retention; dependable hours and low turnover directly support the multiple.
- Assemble the data room. Organize contracts, licenses, leases, payer agreements, org charts, and KPI reports in advance, so diligence moves quickly and confidence stays high.
- Engage a healthcare M&A advisor early. An advisor runs a confidential, competitive process, protects your identity until buyers are NDA-gated, and keeps you focused on operations while they manage the sale.
How long does it take to sell a home health agency?
A typical home health agency sale takes about six to nine months from the start of preparation to closing, and rushing it usually costs value. Building in lead time is what lets you sell from strength instead of scrambling to answer diligence questions after a buyer is already at the table.
Roughly, expect one to three months to prepare financials and materials, one to two months to run a confidential process and collect offers, and three to four months from a signed letter of intent through diligence, regulatory considerations such as Medicare enrollment and any change-of-ownership steps, and closing. Complex payer arrangements, licensing, or accreditation transfers can extend that. This is the practical reason we tell owners to begin six to nine months before they want to be out. The preparation itself often raises the sale price by more than the wait costs.
For a fuller walk-through of the sale process end to end, see our overview of the seven steps to selling a healthcare agency, and our companion guides on home health valuation and exit and succession planning.
Wondering whether now is your moment? Start a confidential conversation with Vallexa Advisors. We will give you a candid read on your timing, a valuation range grounded in current deal data, and a clear path if you decide to move. No pressure, no upfront fee, healthcare-only.
Talk to Vallexa Advisors about selling your home health agency | Try the free valuation calculator
Frequently asked questions
Is 2026 a good time to sell a home health agency?
For a prepared, well-run agency, yes. Buyer demand rebounded in early 2026, home health closed its strongest M&A quarter in over a year, and multiples firmed modestly, while many owners remain on the sidelines. That imbalance favors sellers who have their financials and compliance in order (source: Mertz Taggart, Q1 2026).
How does the CMS CY 2027 proposed rule affect selling?
It signals continued reimbursement volatility, which raises the premium buyers place on durable cash flow. The proposed net 2.4% increase for 2027 is offset by a continuing temporary 3.0% recoupment, and enrollment scrutiny is rising, so clean compliance is now a gating item in diligence (source: CMS-1844-P, July 2026).
What is my home health agency worth?
Most established Medicare-certified agencies are valued on adjusted EBITDA, with illustrative ranges around 6.0x to 8.0x and scaled platforms trading several turns higher. Your actual range depends on payer mix, geography, staffing stability, and referral concentration. A calculator gives a starting estimate; an advisor refines it against your actuals.
Should I sell my home health agency now or wait?
Sell now if earnings are strong, buyers are active, and you are ready to step back. Wait only if you have a concrete, fundable plan to raise value over the next twelve to eighteen months and the energy to execute it. Waiting passively for easier reimbursement rarely pays.
How long does it take to sell a home health agency?
Plan on about six to nine months from preparation to closing: one to three months to ready financials and materials, one to two months to run a process, and three to four months from letter of intent through diligence and Medicare change-of-ownership steps to close. Complex licensing can extend it.
Do I have to tell my staff and referral sources I am selling?
Not during the process. A confidential sale keeps your identity protected until buyers are qualified and under NDA, so staff, referral partners, and competitors are not alerted while you evaluate offers. Maintaining confidentiality is one of the main reasons owners work with an advisor.
What does Vallexa Advisors charge to help me sell?
Vallexa works on a success-based fee, with no upfront cost and no hidden charges, so the initial valuation and timing conversation is free. We focus only on healthcare M&A, which means the process is run by people who understand home health payer mix, compliance, and buyer behavior.
About the author
Jason Atty is the founder of Vallexa Advisors, a healthcare-only M&A advisory firm that helps owners of home health, hospice, and home care agencies understand value, prepare intelligently, and run confidential sale processes that attract qualified buyers. Jason and the Vallexa team advise owners nationwide on timing, valuation, and buyer selection, with a success-based model and a confidentiality-first approach. To start a confidential conversation, visit vallexaadvisors.com.
Educational only. Not legal, financial, or tax advice. Healthcare M&A outcomes depend on specific facts, payer mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything in this document.
Key Takeaways
- The right time to sell a home health agency is when financials are strong, the buyer market is active, and you are ready to step back.
- In 2026, buyer activity has improved, but agency owners need to evaluate their financials and market position.
- The CMS CY 2027 proposed rule indicates ongoing reimbursement fluctuations, which buyers consider when evaluating agency value.
- Prepare your agency by cleaning financials, improving compliance, and reducing owner dependency to maximize sale potential.
- Consider selling now if your agency is ready; wait only if you have a solid plan to enhance value in the near future.
Estimated reading time: 15 minutes
